Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Sage Therapeutics, Inc. - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Sage Therapeutics, Inc. - Product Pipeline Review - 2016', provides an overview of the Sage Therapeutics, Inc.'s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Sage Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Sage Therapeutics, Inc. - The report provides overview of Sage Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Sage Therapeutics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Sage Therapeutics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Sage Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Sage Therapeutics, Inc. - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Sage Therapeutics, Inc.'s pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Sage Therapeutics, Inc. Snapshot 5 Sage Therapeutics, Inc. Overview 5 Key Information 5 Key Facts 5 Sage Therapeutics, Inc. - Research and Development Overview 6 Key Therapeutic Areas 6 Sage Therapeutics, Inc. - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Sage Therapeutics, Inc. - Pipeline Products Glance 11 Sage Therapeutics, Inc. - Late Stage Pipeline Products 11 Phase III Products/Combination Treatment Modalities 11 Sage Therapeutics, Inc. - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 Sage Therapeutics, Inc. - Early Stage Pipeline Products 14 IND/CTA Filed Products/Combination Treatment Modalities 14 Preclinical Products/Combination Treatment Modalities 15 Discovery Products/Combination Treatment Modalities 16 Sage Therapeutics, Inc. - Drug Profiles 17 sepranolone 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 SAGE-217 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 SAGE-689 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 SAGE-105 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 SAGE-324 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 SAGE-718 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 SGE-872 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Small Molecules to Agonize NMDA Receptor for Cognitive Disorders 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 Small Molecules to Agonize NMDA receptor for CNS Disorders 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecules to Modulate GABAA Receptor for CNS Disorders 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Sage Therapeutics, Inc. - Pipeline Analysis 29 Sage Therapeutics, Inc. - Pipeline Products by Target 29 Sage Therapeutics, Inc. - Pipeline Products by Route of Administration 30 Sage Therapeutics, Inc. - Pipeline Products by Molecule Type 31 Sage Therapeutics, Inc. - Pipeline Products by Mechanism of Action 32 Sage Therapeutics, Inc. - Recent Pipeline Updates 33 Sage Therapeutics, Inc. - Dormant Projects 39 Sage Therapeutics, Inc. - Locations And Subsidiaries 40 Head Office 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 41 Disclaimer 42
List of Tables
Sage Therapeutics, Inc., Key Information 5 Sage Therapeutics, Inc., Key Facts 5 Sage Therapeutics, Inc. - Pipeline by Indication, 2016 8 Sage Therapeutics, Inc. - Pipeline by Stage of Development, 2016 9 Sage Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016 10 Sage Therapeutics, Inc. - Phase III, 2016 11 Sage Therapeutics, Inc. - Phase II, 2016 12 Sage Therapeutics, Inc. - Phase I, 2016 13 Sage Therapeutics, Inc. - IND/CTA Filed, 2016 14 Sage Therapeutics, Inc. - Preclinical, 2016 15 Sage Therapeutics, Inc. - Discovery, 2016 16 Sage Therapeutics, Inc. - Pipeline by Target, 2016 29 Sage Therapeutics, Inc. - Pipeline by Route of Administration, 2016 30 Sage Therapeutics, Inc. - Pipeline by Molecule Type, 2016 31 Sage Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016 32 Sage Therapeutics, Inc. - Recent Pipeline Updates, 2016 33 Sage Therapeutics, Inc. - Dormant Developmental Projects,2016 39
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.